Last updated: August 25, 2026
Helsinn Healthcare S.A. sued Sagent Pharmaceuticals, Inc. in the U.S. District Court for the District of New Jersey after Sagent sought FDA approval for a generic palonosetron hydrochloride injection, the active ingredient in Helsinn's Aloxi product. The case, No. 2:16-cv-00173, involved Helsinn's formulation patents covering pharmaceutical compositions containing palonosetron.
The dispute ended without a reported trial or merits judgment. The public docket reflects a settlement-related dismissal. The case therefore established no binding infringement ruling against Sagent, and the commercial terms of the settlement were not publicly disclosed in the docket materials.[1]
What patents protect Aloxi and palonosetron injection?
Helsinn's principal patent position for injectable palonosetron consisted of formulation patents directed to pharmaceutical compositions and dosage forms containing palonosetron hydrochloride.
| Patent |
General subject matter |
Relevance to Sagent case |
Listed expiration |
| U.S. Patent No. 7,947,724 |
Pharmaceutical compositions containing palonosetron |
Asserted formulation patent |
July 25, 2024 |
| U.S. Patent No. 7,960,424 |
Palonosetron pharmaceutical compositions and related formulations |
Asserted formulation patent |
July 25, 2024 |
The patents were distinct from Helsinn's earlier compound and method patents, including U.S. Patent Nos. 5,202,333 and 5,362,718. Those earlier patents covered palonosetron chemistry or therapeutic use and had expired before or around the time of the Sagent litigation. The commercial dispute in 2016 therefore centered on the later formulation patents rather than the basic active pharmaceutical ingredient.[2]
The asserted patent family was important because a generic applicant could avoid expired compound patents yet still face an infringement claim based on the formulation, concentration, excipients, or manufacturing characteristics of the proposed injection.
When did Helsinn file the Sagent patent lawsuit?
Helsinn filed the action on January 12, 2016, in the District of New Jersey under case number 2:16-cv-00173.[1] The complaint followed Sagent's filing of an abbreviated new drug application, or ANDA, seeking approval to market a generic palonosetron hydrochloride injection.
The litigation was an ANDA patent case under the Hatch-Waxman Act. Sagent's regulatory filing triggered a Paragraph IV dispute because the generic applicant challenged the validity, enforceability, or infringement of Helsinn's Orange Book-listed patents.
The filing of the lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination through litigation or settlement. The stay protected Helsinn from immediate FDA approval of the competing product while the patent case proceeded.[3]
What was Sagent's Paragraph IV challenge?
Sagent's ANDA certification placed Helsinn's formulation patents at issue. A Paragraph IV certification represents the applicant's position that an Orange Book-listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.
In practical terms, Sagent's challenge created three principal issues:
- Whether the proposed palonosetron injection fell within the asserted formulation claims.
- Whether the asserted claims were invalid for lack of novelty, obviousness, or inadequate written description.
- Whether Helsinn's patents were enforceable and properly listed for the proposed product.
The public litigation record does not show a final claim-construction ruling, summary judgment decision, bench trial, or Federal Circuit appeal resolving those issues. The case was terminated through settlement rather than an adjudicated infringement decision.[1]
What formulations were protected by Helsinn's patents?
The '724 and '424 patents were directed to injectable palonosetron formulations rather than merely the chemical identity of palonosetron. The claims covered compositions containing palonosetron hydrochloride in defined pharmaceutical formulations, including concentration and excipient limitations.
The formulation strategy created a barrier even after the active ingredient's earlier patent protection had expired. A generic manufacturer could not rely solely on an off-patent active ingredient if its proposed product reproduced the patented formulation or fell within the asserted claim limitations.
The key technical distinction was between:
- The active pharmaceutical ingredient, palonosetron hydrochloride.
- The dosage form, an injectable solution.
- The concentration and volume of the injection.
- The excipient system and pH environment.
- The manufacturing and presentation characteristics of the finished product.
The asserted patents did not provide unlimited control over every palonosetron product. Their scope depended on the exact claim language and the composition disclosed in Sagent's ANDA. That made the ANDA's formulation details central to the infringement analysis.
What was the FDA and Orange Book status of Aloxi?
Aloxi is the brand name for palonosetron hydrochloride injection, marketed by Helsinn for prevention of chemotherapy-induced nausea and vomiting. The FDA Orange Book listed patents associated with Aloxi, including the later formulation patents that supported Helsinn's enforcement actions against generic applicants.[4]
| Regulatory issue |
Status in the Sagent dispute |
| Regulatory pathway |
ANDA approval for generic palonosetron injection |
| Brand product |
Aloxi |
| Active ingredient |
Palonosetron hydrochloride |
| Patent dispute |
Paragraph IV litigation |
| Regulatory effect |
Statutory 30-month stay after suit |
| FDA approval during case |
Blocked pending the statutory stay and case resolution |
| Final approval date for Sagent product |
Not established by the public litigation docket |
The Orange Book listing gave Helsinn the statutory basis to sue after receiving the Paragraph IV notice. The listing did not itself establish infringement. That question depended on the comparison between the asserted claims and Sagent's proposed product.
How strong was Helsinn's patent estate in the Sagent case?
Helsinn's estate was commercially meaningful but concentrated. The earlier compound patents no longer provided a durable barrier by 2016. The remaining protection depended primarily on formulation patents with expiration in 2024.
Strengths
The formulation patents had several strategic advantages:
- They covered the commercial injectable dosage form.
- They extended exclusivity beyond the earlier palonosetron patents.
- They were listed in the Orange Book.
- They supported a Hatch-Waxman suit and a 30-month approval stay.
- They could create launch risk for a generic applicant even where the active ingredient was off patent.
Weaknesses
The estate also had material limitations:
- The patents were scheduled to expire in 2024.
- Their enforceability depended on narrow formulation limitations.
- A generic applicant could design around particular concentration, excipient, or presentation claims.
- A Paragraph IV challenge could attack validity as well as infringement.
- The case ended without a merits ruling confirming claim scope.
The estate was therefore stronger as a settlement and launch-timing asset than as a fully adjudicated monopoly. The absence of a judicial decision left the ultimate validity and infringement risk unresolved.
Which companies challenged Helsinn's Aloxi patents?
Helsinn pursued several ANDA litigations involving generic palonosetron products. The Sagent action formed part of a broader competitive challenge to Aloxi's remaining formulation protection.
Known litigation activity involving Helsinn's palonosetron formulation patents included cases against generic applicants such as:
- Teva Pharmaceuticals.
- Dr. Reddy's Laboratories.
- Sagent Pharmaceuticals.
- Other ANDA filers seeking approval for palonosetron injection.
The most consequential related litigation was Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., which later reached the U.S. Supreme Court on a separate patent-law issue concerning the on-sale bar. That Supreme Court case addressed whether a confidential commercial sale could qualify as prior art under the America Invents Act. It did not decide the merits of the Sagent case.[5]
What was the litigation outcome?
The Sagent case ended by settlement and dismissal. No published opinion reports that the court found Sagent's ANDA product infringing, and no final judgment invalidated the asserted Helsinn patents.
The settlement terms were confidential. The public record does not establish:
- Sagent's agreed launch date.
- Whether Sagent received a license.
- Whether the agreement included a royalty.
- Whether Sagent accepted any patent validity or infringement position.
- Whether Sagent obtained an authorized-generic arrangement.
- Whether the agreement included acceleration or early-entry provisions.
The absence of disclosed terms prevents a definitive determination of the economic value Helsinn assigned to Sagent's potential entry. The procedural result nonetheless indicates that the parties resolved the litigation before a merits determination.
Did the settlement allow generic launch before patent expiration?
The public docket does not disclose a specific Sagent launch date. Because the asserted patents were scheduled to expire in 2024, any settlement-based launch right would have been commercially valuable only if it permitted entry before the ordinary patent expiration date or included a license with conditions more favorable than continued litigation.
A settlement could have used several structures:
- A fixed entry date before expiration.
- A license effective on a specified date.
- Royalty-bearing entry.
- Entry tied to a court decision in related litigation.
- Earlier launch after a triggering event, such as another generic entrant or patent invalidation.
None of those terms should be attributed to Sagent without a public agreement or regulatory record.
What patent litigation affected Helsinn's palonosetron exclusivity?
The broader Aloxi litigation had two layers.
Earlier compound and method patents
Helsinn's earlier patents protected palonosetron as a chemical compound and its therapeutic use. By 2016, those rights had largely expired. They were not sufficient to prevent generic entry on a long-term basis.
Later formulation patents
The '724 and '424 patents extended the enforceable patent position into 2024. Those patents became the principal basis for ANDA litigation and settlement negotiations.
The Supreme Court's later decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. concerned the validity framework for the formulation patent family and the effect of an earlier confidential transaction on the on-sale bar. The Court held that the America Invents Act did not alter the statutory meaning of "on sale" by requiring the sale to be publicly disclosed.[5]
That decision was significant to the broader patent family, but it did not produce a merits judgment in the Sagent docket.
What generic entry risks existed for Sagent?
Sagent faced a conventional ANDA litigation risk profile.
| Risk |
Potential consequence |
| Infringement finding |
Delay or prohibition of generic launch until patent expiration or license date |
| Patent invalidity ruling |
Loss of Helsinn's formulation barrier |
| Non-infringement ruling |
Earlier FDA approval and commercial launch |
| Settlement |
Contractual launch date and possible royalty obligations |
| Regulatory delay |
Approval blocked by the 30-month stay or unresolved certification issues |
| Design-around failure |
Repeated litigation or reformulation costs |
| Commercial timing risk |
Reduced value of entry as patent expiration approached |
The product's injectable nature increased manufacturing and regulatory complexity relative to an ordinary oral solid. A generic entrant needed an FDA-approved sterile manufacturing process, validated container-closure system, stability data, and a formulation that avoided the asserted claims or obtained a license.
How did Helsinn's patent estate compare with ordinary generic-drug cases?
Helsinn's position was stronger than a case involving only an expired active-ingredient patent because the later formulation patents extended the potential exclusion period. It was weaker than a case supported by multiple unexpired compound, formulation, method-of-use, and manufacturing patents.
| Patent estate characteristic |
Helsinn palonosetron position |
| Compound protection |
Largely expired by litigation date |
| Formulation protection |
Unexpired through 2024 |
| Method-of-use protection |
Less central to the Sagent dispute |
| Manufacturing protection |
Relevant to product development but not the primary public basis of the case |
| Regulatory listing |
Orange Book-listed formulation patents |
| Litigation leverage |
High enough to produce ANDA settlement |
| Long-term durability |
Limited by fixed 2024 expiration |
The estate's commercial value depended on timing. In 2016, the formulation patents provided years of remaining life. As expiration approached, the settlement leverage would have declined unless Helsinn obtained a favorable ruling or controlled an important formulation or supply channel.
Did biosimilar law apply to the Sagent case?
No. Biosimilar law did not apply. Sagent was pursuing an ANDA for a generic small-molecule drug, palonosetron hydrochloride. The applicable framework was Hatch-Waxman, including Paragraph IV certification and the 30-month stay.
A biosimilar application under the Biologics Price Competition and Innovation Act applies to biological products, not conventional small-molecule palonosetron injections.[3]
Key Takeaways
- Helsinn sued Sagent on January 12, 2016, in the District of New Jersey under No. 2:16-cv-00173.
- The dispute concerned Sagent's ANDA for generic palonosetron hydrochloride injection.
- The principal patents were U.S. Patent Nos. 7,947,724 and 7,960,424.
- The patents covered injectable palonosetron formulations rather than only the active ingredient.
- The patents were scheduled to expire July 25, 2024.
- The case involved a Paragraph IV certification and triggered the Hatch-Waxman 30-month stay.
- The parties settled before trial or a final merits ruling.
- The public docket does not disclose Sagent's launch date, royalty terms, or other material settlement provisions.
- No biosimilar pathway was involved.
- Helsinn's patent leverage came from formulation protection after earlier compound patents had expired.
FAQs About Helsinn v. Sagent
What drug was at issue in Helsinn v. Sagent?
The case involved palonosetron hydrochloride injection, the generic equivalent of Helsinn's Aloxi product.
Was Sagent found to infringe Helsinn's patents?
No reported merits judgment found Sagent liable for infringement. The case ended through settlement and dismissal.
Did the case invalidate Helsinn's Aloxi patents?
No. The Sagent docket does not report a final invalidity judgment against the asserted patents.
What is the difference between the Sagent and Teva Helsinn cases?
Both involved Helsinn's palonosetron formulation patent family, but the Teva litigation generated the Supreme Court decision on confidential sales and the America Invents Act on-sale bar. The Sagent matter ended without a comparable merits decision.
Could a generic manufacturer avoid the Helsinn patents through a different formulation?
Potentially. Avoidance would depend on whether the alternative formulation fell outside every asserted claim and satisfied FDA requirements. A different concentration, excipient system, or dosage presentation would not automatically eliminate infringement risk.
References
[1] U.S. District Court for the District of New Jersey. (2016). Helsinn Healthcare S.A. v. Sagent Pharmaceuticals, Inc., No. 2:16-cv-00173, docket records.
[2] U.S. Patent and Trademark Office. (2008). U.S. Patent Nos. 7,947,724 and 7,960,424. Washington, DC: U.S. Department of Commerce.
[3] Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
[4] U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: FDA.
[5] Supreme Court of the United States. (2019). Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123.
